EMD Millipore Corporation, 10394 Pacific Center Ct., San Diego, CA 92121, USA.
Biochem J. 2013 Apr 15;451(2):313-28. doi: 10.1042/BJ20121418.
Despite the development of a number of efficacious kinase inhibitors, the strategies for rational design of these compounds have been limited by target promiscuity. In an effort to better understand the nature of kinase inhibition across the kinome, especially as it relates to off-target effects, we screened a well-defined collection of kinase inhibitors using biochemical assays for inhibitory activity against 234 active human kinases and kinase complexes, representing all branches of the kinome tree. For our study we employed 158 small molecules initially identified in the literature as potent and specific inhibitors of kinases important as therapeutic targets and/or signal transduction regulators. Hierarchical clustering of these benchmark kinase inhibitors on the basis of their kinome activity profiles illustrates how they relate to chemical structure similarities and provides new insights into inhibitor specificity and potential applications for probing new targets. Using this broad dataset, we provide a framework for assessing polypharmacology. We not only discover likely off-target inhibitor activities and recommend specific inhibitors for existing targets, but also identify potential new uses for known small molecules.
尽管已经开发出了许多有效的激酶抑制剂,但这些化合物的合理设计策略一直受到靶点多样性的限制。为了更好地了解激酶组中激酶抑制的性质,特别是与非靶点效应的关系,我们使用生化测定法筛选了一组经过精心定义的激酶抑制剂,以测定它们对 234 种活性人激酶和激酶复合物的抑制活性,这些激酶和激酶复合物代表了激酶组树的所有分支。在我们的研究中,我们使用了 158 种最初在文献中被确定为针对作为治疗靶点和/或信号转导调节剂的重要激酶的有效和特异性抑制剂的小分子。根据它们的激酶组活性谱对这些基准激酶抑制剂进行层次聚类,说明了它们与化学结构相似性的关系,并为抑制剂特异性和探索新靶标的潜在应用提供了新的见解。利用这个广泛的数据集,我们提供了一个评估多效性的框架。我们不仅发现了可能的非靶点抑制剂活性,并为现有靶点推荐了特定的抑制剂,还确定了已知小分子的潜在新用途。